Source comparison
Sermorelin vs GH vs SARMs: Bone Density Mechanism Comparison
Primary Action Stimulates endogenous pulsatile GH release from pituitary via GHRH receptor agonism Direct GH receptor activation in liver and peripheral tissues Ghrelin receptor agonism (mimics hunger hormone), stimulates GH release indirectly Sermorelin prese
This comparison does not assign a generated winner or score.
- Primary Action
- Stimulates endogenous pulsatile GH release from pituitary via GHRH receptor agonism
- Direct GH receptor activation in liver and peripheral tissues
- Ghrelin receptor agonism (mimics hunger hormone), stimulates GH release indirectly
- Sermorelin preserves natural pulsatility and avoids receptor downregulation. The physiologically superior approach for long-term skeletal health
- IGF-1 Elevation
- Increases hepatic IGF-1 production indirectly through GH secretion
- Directly stimulates IGF-1 production in liver and local tissues
- Elevates GH and IGF-1, but with inconsistent pulsatility and higher variability
- Sermorelin produces more stable, sustained IGF-1 elevation without the supraphysiological spikes seen with exogenous GH
- Osteoblast Effect
- IGF-1-mediated upregulation of osteoblast differentiation and activity
- Direct and IGF-1-mediated osteoblast stimulation (dual pathway)
- Primarily IGF-1-mediated, but less predictable due to ghrelin pathway interference
- Exogenous GH offers faster onset but higher risk of adverse metabolic effects; sermorelin provides slower, safer osteoblast activation
- Bone Resorption Impact
- Mild reduction in osteoclast activity through IGF-1 modulation
- Suppresses osteoclast activity more aggressively, which can impair remodeling balance long-term
- No direct effect on osteoclast activity
- Sermorelin's gentler modulation preserves healthy bone turnover. Excessive osteoclast suppression (seen with bisphosphonates and high-dose GH) increases fracture risk due to accumulated microdamage
- Regulatory Status
- Prescription-required peptide, FDA oversight for off-label use
- Prescription-required (Schedule III in some jurisdictions), tightly regulated
- Not FDA-approved for human use, sold as research chemicals only
- Sermorelin is legally prescribed off-label for aging-related GH decline; exogenous GH is restricted to documented GH deficiency; SARMs carry significant legal and safety uncertainty
- Adverse Event Profile
- Minimal at therapeutic doses (200–500 mcg/day); occasional injection-site reactions, transient flushing
- Edema, joint pain, insulin resistance, carpal tunnel syndrome at supraphysiological doses
- Appetite stimulation, water retention, potential impact on glucose metabolism
- Sermorelin's safety margin is substantially wider. It cannot push GH or IGF-1 beyond physiological ceilings, unlike exogenous GH